Share on StockTwits
 

GlaxoSmithKline plc (LON: GSK) was the recipient of a ratings changes during the seven days:

  • GlaxoSmithKline plc had its price target lowered by analysts at Societe Generale from GBX 1,960 ($32.16) to GBX 1,950 ($31.99). They now have a “buy” rating on the stock.
  • GlaxoSmithKline plc had its “neutral” rating reaffirmed by analysts at UBS AG. They now have a GBX 1,650 ($27.07) price target on the stock.
  • GlaxoSmithKline plc had its price target lowered by analysts at Deutsche Bank from GBX 1,700 ($27.89) to GBX 1,620 ($26.58). They now have a “hold” rating on the stock.
  • GlaxoSmithKline plc had its “hold” rating reaffirmed by analysts at Panmure Gordon. They now have a GBX 1,750 ($28.71) price target on the stock.
  • GlaxoSmithKline plc had its “underperform” rating reaffirmed by analysts at BNP Paribas. They now have a GBX 1,600 ($26.25) price target on the stock.
  • GlaxoSmithKline plc had its “neutral” rating reaffirmed by analysts at Citigroup Inc.. They now have a GBX 1,810 ($29.70) price target on the stock.
  • GlaxoSmithKline plc had its price target lowered by analysts at Jefferies Group from GBX 1,750 ($28.71) to GBX 1,650 ($27.07). They now have a “hold” rating on the stock.
  • GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Kepler Capital Markets. They now have a GBX 1,800 ($29.53) price target on the stock.

GlaxoSmithKline plc (LON:GSK) opened at 1651.50 on Thursday. GlaxoSmithKline plc has a 52-week low of GBX 1444.50 and a 52-week high of GBX 1816.00. The stock’s 50-day moving average is GBX 1606. and its 200-day moving average is GBX 1617.. The company’s market cap is £79.123 billion.

GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.